2018
Alcohol withdrawal hallucinations in the general population, an epidemiological study
Stephane M, Arnaout B, Yoon G. Alcohol withdrawal hallucinations in the general population, an epidemiological study. Psychiatry Research 2018, 262: 129-134. PMID: 29433107, DOI: 10.1016/j.psychres.2018.02.021.Peer-Reviewed Original ResearchConceptsOdds ratioBrain developmentHigher odds ratioLogistic regression analysisMost psychiatric illnessesNational Epidemiologic SurveyAlcohol withdrawalClinical patternWithdrawal seizuresPsychiatric comorbidityMechanisms of hallucinationsPsychiatric illnessUnmarried subjectsEpidemiological studiesGeneral populationEpidemiologic SurveyRelated conditionsAnxiety disordersLow levelsSevere exposureHallucinationsSocial isolationRegression analysisAfrican AmericansSuch history
2007
Aripiprazole as an adjunctive treatment for refractory unipolar depression
Hellerstein DJ, Batchelder S, Hyler S, Arnaout B, Corpuz V, Coram L, Weiss G. Aripiprazole as an adjunctive treatment for refractory unipolar depression. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2007, 32: 744-750. PMID: 18164528, DOI: 10.1016/j.pnpbp.2007.11.024.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsAripiprazoleBrief Psychiatric Rating ScaleDepressive DisorderDiagnostic and Statistical Manual of Mental DisordersDrug Administration ScheduleDrug EvaluationFemaleHumansMaleMiddle AgedPiperazinesProspective StudiesQuinolonesSocial BehaviorTime FactorsTreatment OutcomeConceptsHDRS-24Adjunctive treatmentSNRI medicationsUnipolar depressionCurrent episodeWeek open label studyTreatment-resistant major depressionCurrent DSM-IV diagnosisEffectiveness of aripiprazoleRefractory unipolar depressionOpen-label studyEffective adjunctive treatmentDSM-IV diagnosisFluoxetine equivalentsSNRI treatmentWeek 12Baseline severityMean doseMajor depressionTreatment respondersSide effectsSSRIsMaximum doseAripiprazoleMedications